Acute Sinusitis Antibiotic Evidence

Acute rhinosinusitis is one of the most common conditions in primary care, accounting for approximately 1 in 5 adult antibiotic prescriptions. For decades, antibiotics were prescribed routinely based on the assumption that bacterial infection was the primary driver of symptoms. However, distinguishing bacterial from viral sinusitis clinically is extremely difficult, and most cases of acute rhinosinusitis are viral in etiology and self-limited. Early placebo-controlled trials and Cochrane reviews in the 1990s-2000s began to question the magnitude of antibiotic benefit, showing only marginal improvements in symptom resolution — typically shortening illness by 1-2 days — with significant rates of adverse effects.

The Garbutt trial, published in JAMA in 2012, was a landmark US RCT that provided clear evidence against routine antibiotic use in acute sinusitis. This trial randomized 166 adults with acute rhinosinusitis (diagnosed by clinical criteria including purulent nasal discharge, facial/dental pain, and duration >7 days) to amoxicillin 1500mg/day or placebo for 10 days. There was no significant difference in symptom improvement at day 3 (primary endpoint) or at any other time point through day 28. The Williamson trial (Lancet 2007) had similarly found that neither amoxicillin nor topical nasal steroids provided meaningful benefit over placebo. These definitive RCTs, combined with Cochrane meta-analyses, established that antibiotics provide minimal benefit for uncomplicated acute sinusitis and that the vast majority of cases resolve spontaneously.

Updated Cochrane reviews confirmed that antibiotics produce a small but statistically significant benefit — approximately 5 more people per 100 are cured at 7-14 days compared to placebo — but this comes with an NNT of 18 and an NNH (for adverse effects) of 8, meaning more patients are harmed than helped. Research focused on identifying the subset of patients who might genuinely benefit from antibiotics: those with severe symptoms (high fever, facial swelling), symptoms lasting >10 days without improvement, or double-worsening (improvement followed by deterioration). Imaging studies confirmed that CT findings of sinusitis are present in up to 87% of patients with common colds, further demonstrating that radiographic findings do not indicate bacterial infection or the need for antibiotics.

The IDSA clinical practice guideline (2012) takes a more aggressive approach, recommending antibiotics for acute bacterial rhinosinusitis diagnosed by specific criteria (symptoms ≥10 days without improvement, severe symptoms with high fever for 3-4 days, or double-worsening). In contrast, the AAO-HNS (2015) and AAP guidelines recommend watchful waiting as an acceptable initial strategy for uncomplicated acute sinusitis with mild-moderate symptoms, with antibiotics reserved for failure to improve after 7-10 days or severe presentations. NICE (UK) recommends no antibiotic or delayed antibiotic prescriptions for most cases. This divergence reflects the tension between infectious disease specialists (who focus on bacterial diagnosis) and primary care/otolaryngology guidelines (which prioritize antimicrobial stewardship).

Despite strong evidence against routine antibiotics for acute sinusitis, antibiotic prescribing rates remain stubbornly high in many countries, driven by patient expectations, diagnostic uncertainty, and time pressure in primary care consultations. Antimicrobial stewardship programs increasingly target sinusitis as a high-impact condition for reducing unnecessary antibiotic use. Delayed prescribing strategies (providing a prescription to be filled only if symptoms worsen or persist) offer a pragmatic middle ground that reduces antibiotic use by 50-60% while maintaining patient satisfaction. Point-of-care inflammatory biomarkers (CRP, procalcitonin) are being studied as tools to guide antibiotic decisions but are not yet standard practice for sinusitis. The central message remains that most acute sinusitis is viral, self-limited, and best managed with symptomatic treatment and watchful waiting.